Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Grifols S.A.. (1/26/18). "Press Release: Grifols Reinforces Its Hospital Division by Acquiring a 51% Stake in the U.S. Technology Firm MedKeeper for USD 98 Million". Barcelona.

Region Region Denver, CO
  Country United States (USA)
Organisations Organisation Grifols Shared Services North America Inc.
  Group Grifols (Group)
  Organisation 2 Goetech LLC (d/b/a MedKeeper)
  Group Grifols (Group)
Products Product healthcare informatics
Index term Index term Goetech–Grifols: investment, 201801 acquisition $98m of 51% stake in Goetech LLC (d/b/a MedKeeper) by Grifols

> MedKeeper is a technology firm that develops and markets mobile and webbased software applications for hospital pharmacies.

> Its PharmacyKeeper portfolio offers solutions that optimize operational efficiency, increase process safety, improve communications throughout the value chain and enhance compliance.

> Aligned with its corporate strategy, Grifols complements its Pharmatech line, the main business of its Hospital Division, and reinforces its presence in the U.S. market.

Barcelona, January 26, 2018.- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a global leader in the production of plasma-derived medicines and a research pioneer on alternative therapies that contribute toward scientific and social advancement, announced the acquisition of a 51% equity stake in Goetech LLC, whose trade name is MedKeeper, for USD 98 million.

The transaction was executed through a subscription of a capital increase, without debt issuance. Grifols holds a majority position on the Board of Directors of MedKeeper. As part of the agreement, Grifols also negotiated a call option to acquire the remaining 49% interest within three years. MedKeeper holds a put option to sell Grifols said interest that can be executed at the end of the three years period.

The transaction has been made through Grifols Shared Services North America, Inc.

Grifols continues to advance its strategic plan to reinforce the Hospital Division by investing in technology-based innovations that complement its core portfolio of products for hospital pharmacies. The transaction also accelerates Grifols Hospital Division global expansion by increasing its presence in the U.S. market.

MedKeeper’s capabilities complement the line of hospital-pharmacy products that Grifols already markets on a global scale. Grifols already develops equipment and technology to automate and monitor key hospital-management processes, including those related to the safety of patients and healthcare professionals.

Established in 2001, MedKeeper is a Denver, Colorado-based emerging integrated technology firm that creates mobile and web-based technology solutions designed to improve efficiency and safety, as well as enhance compliance with key processes in hospital pharmacy operations.

MedKeeper’s product portfolio uses leading-edge technology to design fast, flexible and customer-centric software applications.

These applications include among others, a medication workflow system to increase staff efficiency and ensure compliance with applicable compounding regulations; a medication tracking system to reduce turnaround times and improve communications throughout the value chain; a training system to create, schedule and manage team’s competencies, certifications and training all in one platform; and a medication checklist system to ensure compliance with standards for medication storage and inspections.

About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols’ three main divisions - Bioscience, Diagnostic and Hospital - develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of more than 180 plasma donation centers, Grifols is a leading producer of plasmaderived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has approximately 18,000 employees in 30 countries.

In 2016, sales exceeded 4,000 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit

Investors contact:

Investor Relations Department -
Phone number: +34 93 571 02 21

Media contact:
Raquel Lumbreras
Borja Gómez
Duomo Comunicación - Grifols Press Office
Phone number: +34 91 311 92 89 - +34 91 311 92 90


The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Record changed: 2018-04-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for Grifols (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top